The Royal College of Physicians Report on E-cigarette Use

Regulations by 2FIRSTS.ai
Apr.24.2024
The Royal College of Physicians Report on E-cigarette Use
In a new report, the Royal College of Physicians suggests that e-cigarettes are effective for quitting smoking but need regulation.

According to a report released by the Royal College of Physicians (RCP) on April 23, e-cigarettes are an effective aid for quitting smoking. However, more measures should be taken to reduce the appeal, availability, and affordability of e-cigarettes to non-smokers, as well as minimize their impact on the environment.

 

The results were summarized into over 50 recommendations, which explored trends in the use of combustible tobacco and e-cigarette products, differences in the health impacts of e-cigarettes on smokers, non-smokers, or both, as well as environmental damage, and the role of e-cigarette use in the expansion of the tobacco industry.

 

The conclusion of the RCP report is that since the 2016 RCP report, the evidence of the effectiveness of e-cigarette-assisted smoking cessation has become stronger. In recent years, there has been a significant increase in the number of young people and non-smokers using e-cigarettes, so timely remedial measures are needed to curb youth e-cigarette use while not affecting the use of e-cigarettes as a smoking cessation aid for adults. The government should commission regular updates on the evidence of the use and impact of nicotine products to guide policies.

 

Researchers emphasize that e-cigarettes should be promoted as an effective tool to help smokers quit smoking, particularly focusing on those who stand to benefit the most, such as individuals with mental health disorders or those in socioeconomically disadvantaged positions, or living in social housing.

 

Researchers reviewed the potential adverse effects of using e-cigarette products on health by examining biomarkers of e-cigarette exposure and harm from data released between 2021 and 2023. They compared e-cigarette users, smokers, dual users (both using e-cigarettes and smoking), and non-users of both products.

 

Although harmful substance levels of e-cigarette users are found to be lower than smokers in many biomarker analyses, researchers have concluded the need for consensus on methods for studying the health risks of e-cigarettes. This includes determining which biomarkers are most relevant in relative and absolute studies. Larger sample studies are necessary for both e-cigarette users with a history of smoking and those who have never smoked in order to reach accurate conclusions.

 

When it comes to teenage addiction issues, researchers at the RCP have concluded that standardized plain packaging should be introduced, flavors and brand descriptions should be reduced, and retail display bans should be implemented to decrease teenagers' interest in trying e-cigarettes. Price and tax strategies for e-cigarettes should make the most commonly used and cheapest product by teenage e-cigarette users (disposable e-cigarettes) less affordable, while ensuring that products most likely to be used by adults who smoke or are trying to quit (rechargeable and refillable e-cigarettes) have minimal environmental impact and remain affordable.

 

The report also suggests increasing prices by imposing a consumption tax and setting minimum prices, prohibiting multiple purchases, but ensuring that they remain a more affordable option for adults who use them to quit smoking. It also recommends limiting the visibility of promotional materials in retail stores and products, as well as restricting promotional activities on social media. At the same time, the report authors are urging regulatory agencies to prevent cigarette manufacturers from influencing national policy-making.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
HM Revenue & Customs put the UK's Vaping Products Duty and Vaping Duty Stamps Scheme into effect on October 1. All vaping liquids manufactured in or imported into the UK are now subject to duty at £2.20 per 10ml, regardless of nicotine content. The stamp regime will introduce digital functionality designed to provide traceability throughout the supply chain, with approved manufacturers, importers and warehousekeepers required to report product movements and retailers and consumers eventually able to scan stamps to verify authenticity. China exported $177 million of vape-related products to the UK in August, up 51.4% year over year, increasing the significance of the new compliance regime for China's Shenzhen-centered vape supply chain.
Regulations
Oct.04
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
India Duty-Free Nicotine Pouch Sales Face Regulatory Test as ZYN, FOX Classification Remains Open
The Bombay High Court has ruled that airport duty-free shops are not exempt from India's domestic regulatory laws merely because they operate beyond the customs barrier, leaving in place a sales halt covering ZYN and FOX nicotine pouches at Mumbai's international airport. The court, however, did not determine that the products necessarily qualify as "drugs" under India's Drugs and Cosmetics Act. The retailers have four weeks to submit product information to the appropriate authorities, including CDSCO, which must complete its review within 30 days of receiving the submissions.
Sep.24
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Latest UK ONS Data: 54% of Vapers Are Former Cigarette Smokers, 26% Also Smoke and 20% Never Smoked Regularly
Former cigarette smokers accounted for an estimated 54% of current e-cigarette users in Great Britain in 2025, while 26% also smoked cigarettes and 20% had never regularly smoked, according to a 2Firsts analysis of Office for National Statistics (ONS) data. Among former cigarette smokers who currently vape, approximately 81% used e-cigarettes daily, compared with about 50% of dual users. The ONS found that 33.8% of current cigarette smokers also vaped in 2025, up from 10.6% in 2014. Approximately 1.1 million adults who had never regularly smoked cigarettes used e-cigarettes, representing 2.9% of that population, compared with 0.2% in 2014. The figures highlight differences in the composition, frequency of use and long-term trends across Britain's vaping population.
DATA
Oct.14
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10